版本:
中国

BRIEF-Tesaro initiates registrational development program for anti-pd-1 antibody TSR-042

April 27 Tesaro Inc

* Tesaro initiates registrational development program for anti-pd-1 antibody tsr-042

* Tesaro inc - ongoing clinical trial expanded to enroll patients with endometrial cancer

* Tesaro inc- intend to continue efforts with future combination studies of tsr-042 and zejula Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐